Blood:转录因子ETS1调控NK细胞发育和终末分化

2020-05-04 QQY MedSci原创

人ETS1缺乏会抑制几种NK细胞相关关键转录因子的表达和NK细胞的分化。 ETS1对于肿瘤细胞诱导性NK细胞毒性和IFN-γ的产生必不可少。

中心点:

人ETS1缺乏会抑制几种NK细胞相关关键转录因子的表达和NK细胞的分化。

ETS1对于肿瘤细胞诱导性NK细胞毒性和IFN-γ的产生必不可少。

摘要:

自然杀伤细胞(NK)在肿瘤细胞和病原体的免疫防御中发挥重要作用,并通过细胞因子的分泌调节其他免疫细胞。虽然小鼠NK细胞的生物学已经被广泛研究,但有关转录通路调控人类NK细胞发育和成熟的知识却很有限。

通过产生ETS1缺陷的人类胚胎干细胞(hESC)和在脐血(CB)造血祖细胞(HPCs)中表达显性阴性ETS1 p27亚型,研究人员发现转录因子ETS1是人NK细胞分化的关键因子。

RNA测序结合染色质免疫沉淀(ChIP-seq)的全基因组转录组分析显示,人类ETS1可直接诱导控制NK细胞分化的关键转录因子E4BP4、TXNIP、TBET、GATA3、HOBIT和BLIMP1的表达。

此外,ETS1还调控凋亡和NK细胞活化相关基因的表达。

本研究揭示了ETS1作为人类NK细胞发育和终末分化的重要调控因子的分子机制。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747391, encodeId=14e91e473919b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jul 21 16:56:19 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952183, encodeId=d8691952183c9, content=<a href='/topic/show?id=a9f0e068ab' target=_blank style='color:#2F92EE;'>#ETS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7068, encryptionId=a9f0e068ab, topicName=ETS1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 11 07:56:19 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347472, encodeId=655f134e4721c, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537495, encodeId=421c153e495cf, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-07-21 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747391, encodeId=14e91e473919b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jul 21 16:56:19 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952183, encodeId=d8691952183c9, content=<a href='/topic/show?id=a9f0e068ab' target=_blank style='color:#2F92EE;'>#ETS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7068, encryptionId=a9f0e068ab, topicName=ETS1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 11 07:56:19 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347472, encodeId=655f134e4721c, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537495, encodeId=421c153e495cf, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2021-02-11 dingxiaobo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747391, encodeId=14e91e473919b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jul 21 16:56:19 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952183, encodeId=d8691952183c9, content=<a href='/topic/show?id=a9f0e068ab' target=_blank style='color:#2F92EE;'>#ETS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7068, encryptionId=a9f0e068ab, topicName=ETS1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 11 07:56:19 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347472, encodeId=655f134e4721c, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537495, encodeId=421c153e495cf, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-05-06 neurowu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747391, encodeId=14e91e473919b, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jul 21 16:56:19 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952183, encodeId=d8691952183c9, content=<a href='/topic/show?id=a9f0e068ab' target=_blank style='color:#2F92EE;'>#ETS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7068, encryptionId=a9f0e068ab, topicName=ETS1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Feb 11 07:56:19 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347472, encodeId=655f134e4721c, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537495, encodeId=421c153e495cf, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed May 06 08:56:19 CST 2020, time=2020-05-06, status=1, ipAttribution=)]

相关资讯

再次实锤!抗癌起效竟是因为NK细胞 免疫治疗重大新发现!

由美国希望之城国家医疗中心的科学家开展的一项最新研究,惊讶的发现,免疫治疗中通常被忽略的自然杀伤细胞(NK细胞),居然在检查点抑制剂治疗中起到了至关重要的作用!这项研究最新发表在《Cancer Discovery》上,研究再次刷新了我们对免疫检查点抑制剂治疗的认知!一些癌症患者体内的NK细胞,居然同样也能够表达PD-L1蛋白,而免疫检查点抑制剂能够促进这类NK细胞杀灭肿瘤。研究解决了一个临床上出现

Nat Comm:清华董忠军组首次报道NK细胞功能获得的遗传证据

NK细胞是第三大类天然免疫细胞,担负着先天免疫防御的重任,主要负责清除机体不需要的“非我”细胞,如病毒感染细胞、肿瘤细胞以及异基因骨髓细胞。NK细胞识别“自我”和“非我”的机制是NK细胞领域内关键科学问题。不同于后天获得性免疫,NK细胞的激活或者抑制主要取决于其表面的活化性受体和抑制性受体。主要组织相容性复合体-I类分子(MHC-I)被认为是一种“自我”分子,它可以结合NK细胞表面抑制性受体,从而

Blood:KIR2DS1/KIR3DL1基因型能否指导选择造血细胞抑制的更佳非亲缘供体?

几项研究表明,利用杀伤细胞免疫球蛋白样受体介导的自然杀伤(NK)细胞反应活性可以降低异基因造血细胞移植(HCT)后的复发风险。基于一个有希望的模型,KIR2DS1和KIR3DL1及其同源配体的信息可被用来将供体分为KIR-优势或KIR-劣势。本研究拟从外部在非亲缘供体HCT中验证该模型。采用Cox回归模型检测预测指标对总体存活率(OS)和复发概率的影响,并根据患者年龄、校正的疾病风险指数、表现状态

Blood:HLA-B-21二态性可决定急性髓系白血病免疫疗法的临床预后

NK细胞的功能受杀伤性免疫球蛋白样受体家族(KIRs)和NKG2A/CD94异二聚体这类的抑制性受体调孔。这些受体识别候选靶细胞上的I类HLA同源分子;最近有研究表明,在编码先导肽的基因片段中-21位置上的HLA-B的二态性决定了NK细胞的调控主要是依赖KIRs还是NKG2A/CD94受体。但HLA-B二态性对NK细胞介导的白血病细胞破坏或白血病进程的影响尚不明确。在本研究中,Alexander

FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验

NKMax America是一家生物技术公司,开发自然杀手(NK)细胞疗法,利用人体免疫系统发挥抗肿瘤作用,今天宣布美国食品和药物管理局FDA已接受SNK01的研究性新药(IND)申请。SNK01是一种自体NK细胞过继免疫治疗候选药物,申请用于治疗病理证实的常规治疗难以治愈的癌症患者。

Blood:AML激活AHR通路干扰NK细胞发育并破坏其功能,进一步实现免疫逃逸

中心点:AML的AHR通路激活,可调控miR-29b的表达,干扰NK细胞发育、影响其功能。AHR拮抗剂可逆转AML诱导的NK细胞发育障碍及其功能损伤。摘要:急性髓系白血病(AML)可通过抑制自然杀伤细胞(NK)的发育及其细胞功能,进而逃避小鼠和人类的固有免疫系统。这在一定程度上是通过过表达AML患者NK细胞的microRNA(miR)-29b来实现的,但其潜在机制尚不清楚。Steven D. Sc